Protalix BioTherapeutics CEO outlines 2026 priorities, highlights progress across clinical pipeline

Impact · against what's priced in

Protalix provides positive catalysts via the FDA clearance for PRX-115's Phase 2 trial and favorable Phase 1 data, while introducing a near-term binary event regarding the EMA dosing appeal for Elfabrio. The update confirms that the primary revenue driver, Elfabrio, is tracking to plan.

PLX+0.40

No priced-in read yet